申请人:Anzalp Pharmasolutions Pvt. Ltd.
公开号:US20210161927A1
公开(公告)日:2021-06-03
A new isoform of 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3/4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate (Remdesivir) having increased water solubility is disclosed, along with methods for making the same. Also disclosed are solid and liquid pharmaceutical compositions suitable for treating viral infections such as Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, or Paramyxoviridae viral infections which contain an effective amount of Remdesivir prepared according to the inventive method and the use of those compositions for treating such viral infections.
本文披露了一种新的2-乙基丁基(2S)-2-[[[(2R,3S,4R,5R)-5-(4-氨基吡咯[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3/4-二羟基氧戊二糖-2-基]甲氧基-苯氧基磷酸酯]氨基]丙酸酯(Remdesivir)的异构体,其具有增加的水溶性,同时还披露了制造该异构体的方法。此外,还披露了固体和液体制剂,适用于治疗病毒感染,如Arenaviridae、Coronaviridae、Filoviridae、Flaviviridae或Paramyxoviridae病毒感染,其中含有根据本发明方法制备的有效量的Remdesivir,以及使用这些制剂治疗此类病毒感染的方法。